Blood test to predict treatment response in glioblastoma
Part of Cancer clinical trials.
This study looks at whether a blood marker called CD146 can help predict how well patients with a recurrent brain tumor (glioblastoma) respond to a treatment called bevacizumab. The goal is to see if this test can help doctors personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called glioblastoma that has returned after initial treatment.
- Your tumor is IDH wildtype (a specific genetic type) and has returned.
- You have already had standard first treatment, which includes radiation and chemotherapy.
- You are a candidate for a drug called bevacizumab, which is given for recurrent disease.
- You are able to have MRI scans to monitor your tumor.
- Your overall health level (KPS score) is 60% or higher, meaning you can care for most daily needs.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood test markers that may predict who survives at 6 months after starting bevacizumab for glioblastoma that has come back. It does not aim to cure the cancer by itself, but to improve doctors’ ability to choose the most helpful treatment plan.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This study looks at whether brain scans (MRI, PET/CT) can help predict the genetic makeup of glioblastoma, without needing more tissue samples. If you join, you'll get advanced imaging to better understand your tumor and guide future treatment decisions.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.